Good or excellent response: intermediate‐term duration of intervention Global assessment of symptom scores · patients with chronic spontaneous urticaria
Loratadine 10 mg showed no clear difference in good or excellent response: intermediate‐term duration of… compared with mizolastine 10 mg (low certainty).
1 finding from 1 review
Complete cessation of urticaria: intermediate‐term duration of intervention Global assessment of symptom scores · patients with chronic spontaneous urticaria
Loratadine 10 mg showed no clear difference in complete cessation of urticaria: intermediate‐term duration of… compared with emedastine 2 mg (moderate certainty).
1 finding from 1 review
Good or excellent response: intermediate‐term duration of intervention Global assessment of symptom scores · patients with chronic spontaneous urticaria
Loratadine 10 mg showed no clear difference in good or excellent response: intermediate‐term duration of… compared with emedastine 2 mg (moderate certainty).
1 finding from 1 review
Complete suppression of urticaria: short‐term duration of intervention Global assessment of symptom scores · patients with chronic spontaneous urticaria
Loratadine 10 mg showed no clear difference in complete suppression of urticaria: short‐term duration of… compared with hydroxyzine 25 mg (low certainty).
1 finding from 1 review
Complete suppression of urticaria: short‐term duration of intervention (desloratadine 5 mg) Global assessment of symptom scores · patients with chronic spontaneous urticaria
1 finding from 1 review
Complete suppression of urticaria: short‐term duration of intervention (desloratadine 10 mg) Global assessment of symptom scores · patients with chronic spontaneous urticaria
1 finding from 1 review
Complete suppression of urticaria: short‐term duration of intervention (desloratadine 20 mg) Global assessment of symptom scores · patients with chronic spontaneous urticaria
1 finding from 1 review
Complete suppression of urticaria: intermediate‐term duration of intervention (desloratadine 5 mg) Global assessment of symptom scores · patients with chronic spontaneous urticaria
1 finding from 1 review
Complete suppression of urticaria: short‐term duration of intervention (levocetirizine 5 mg) Global assessment of symptom scores · patients with chronic spontaneous urticaria
1 finding from 1 review
Complete suppression of urticaria: short‐term duration of intervention (levocetirizine 10 mg) Global assessment of symptom scores · patients with chronic spontaneous urticaria
1 finding from 1 review
Rebleeding · patients with upper gastrointestinal bleeding
Tranexamic acid may leads to lower rebleeding Clinical and endoscopic assessment compared with placebo (low certainty).
1 finding from 1 review
Thromboembolic events · patients with upper gastrointestinal bleeding
Tranexamic acid probably leads to higher any thromboembolic event Clinical and radiological assessment compared with placebo (moderate certainty).
1 finding from 1 review
Rebleeding · patients with upper gastrointestinal bleeding
Tranexamic acid probably leads to lower rebleeding Clinical and endoscopic assessment compared with cimetidine or lansoprazole (moderate certainty).
1 finding from 1 review
Safety assessments ‐ medium term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptom Severity Scale (Levine) at 3 months or less Participants' self assessment questionnaire. Scale from: 1 to 5. · carpal tunnel syndrome
1 finding from 1 review
Functional ability · carpal tunnel syndrome
1 finding from 1 review
Symptom Severity Scale (Levine) at more than 3 months Participants' self assessment questionnaire. Scale from: 1 to 5. · carpal tunnel syndrome
1 finding from 1 review
Function Status Scale (Levine) at more than 3 months Participants' self assessment questionnaire. Scale from: 1 to 5. · carpal tunnel syndrome
1 finding from 1 review
Short‐term (1 week) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (1 week) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review